Literature DB >> 32469121

Irisin, an exercise myokine, potently suppresses tumor proliferation, invasion, and growth in glioma.

Chiun-Wei Huang1, Yu-Hsuan Chang2, Hsuan-Hung Lee2, Jing-Yi Wu2, Jia-Xing Huang2, Yi-Hsiu Chung1, Shih-Ting Hsu1, Lu-Ping Chow3, Kuo-Chen Wei4,5, Feng-Ting Huang2.   

Abstract

Glioblastoma multiforme is the most common and aggressive glial tumor with poor prognosis. Importantly, effective treatment options for glioblastoma are unmet needs. Obesity and low physical activity have been linked with a high risk of cancer, and exercise is related to delayed cancer development and progression. Epidemiological studies have revealed a correlation between exercise and the survival rate of patients with glioblastoma. Nevertheless, the mechanisms by which exercise exerts its anticancer effects in glioblastoma remain unclear. Here, we found that irisin, an exercise-induced myokine, induced G2 /M cell cycle arrest and increased p21 levels in glioblastoma cells, leading to the inhibition of cell proliferation. In addition, irisin inhibited glioblastoma cell invasion by upregulating TFPI-2 and even reversed the aggressive tumor phenotype promoted by co-cultivation with cancer-associated adipocytes. Furthermore, irisin retarded xenograft glioblastoma tumor growth, and radiolabeled irisin demonstrated specific tumor-targeting capability in vivo. Therefore, this study identified one potential molecular mechanism by which exercise prevents cancer progression via irisin. Intriguingly, irisin has the potential to be developed as a molecular imaging and therapeutic anticancer agent.
© 2020 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  TFPI-2; cell invasion; exercise; glioblastoma; irisin; tumor targeting

Year:  2020        PMID: 32469121     DOI: 10.1096/fj.202000573RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  8 in total

Review 1.  The role of Irisin in multiorgan protection.

Authors:  Jun Ma; Ken Chen
Journal:  Mol Biol Rep       Date:  2021-01-03       Impact factor: 2.316

2.  Physical Training Protects Against Brain Toxicity in Mice Exposed to an Experimental Model of Glioblastoma.

Authors:  Amanda K Costa; Luis F B Marqueze; Bruna B Gattiboni; Giulia S Pedroso; Franciane F Vasconcellos; Eduardo B B Cunha; Hanna C Justa; Antonielle B Baldissera; Seigo Nagashima; Lucia de Noronha; Zsolt Radak; Luiz C Fernandes; Ricardo A Pinho
Journal:  Neurochem Res       Date:  2022-07-29       Impact factor: 4.414

Review 3.  Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors.

Authors:  Argyro Papadopetraki; Maria Maridaki; Flora Zagouri; Meletios-Athanasios Dimopoulos; Michael Koutsilieris; Anastassios Philippou
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

Review 4.  Implication of Irisin in Different Types of Cancer: A Systematic Review and Meta-Analysis.

Authors:  Maria Vliora; Eleni Nintou; Eleni Karligiotou; Leonidas G Ioannou; Elisabetta Grillo; Stefania Mitola; Andreas D Flouris
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

Review 5.  Role of irisin in physiology and pathology.

Authors:  Shiqiang Liu; Fengqi Cui; Kaiting Ning; Zhen Wang; Pengyu Fu; Dongen Wang; Huiyun Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-26       Impact factor: 6.055

Review 6.  Current Evidence of the Role of the Myokine Irisin in Cancer.

Authors:  Evangelia Tsiani; Nicole Tsakiridis; Rozalia Kouvelioti; Alina Jaglanian; Panagiota Klentrou
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 7.  Integrin-Ligand Interactions in Inflammation, Cancer, and Metabolic Disease: Insights Into the Multifaceted Roles of an Emerging Ligand Irisin.

Authors:  Eun Jeong Park; Phyoe Kyawe Myint; Atsushi Ito; Michael G Appiah; Samuel Darkwah; Eiji Kawamoto; Motomu Shimaoka
Journal:  Front Cell Dev Biol       Date:  2020-10-26

Review 8.  Molecular Mechanisms of Drug Resistance in Glioblastoma.

Authors:  Maya A Dymova; Elena V Kuligina; Vladimir A Richter
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.